현대바이오랜드
Financials
Valuation Metrics
현대바이오랜드's Market Cap is ₩1233B. At end of 2025 it was ₩1289B. Ranked #1086 of 2,405 in KR market (top 45%), #561 of 1,627 on KOSDAQ (top 34%), #25 of 56 in Household & Personal Products (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 123.30B KRW | KR#1,086/2,405 Sec#25/56 |
| Revenue | 140.70B KRW | KR#1,224/2,405 Sec#27/56 |
| Net Income | 13.35B KRW | KR#866/2,405 Sec#21/56 |
| Total Assets | 166.29B KRW | KR#1,434/2,405 Sec#27/56 |
| Net Assets | 145.56B KRW | KR#1,157/2,405 Sec#21/56 |
| Employees | 347 | KR#693/2,405 Sec#15/56 |
| Value | ||
| P/E | 9.24x | KR#813/2,405 Sec#15/56 |
| P/B | 0.85x | KR#1,384/2,405 Sec#31/56 |
| P/S | 0.88x | KR#1,358/2,405 Sec#31/56 |
| EV/EBITDA | 8.32x | KR#545/2,405 Sec#12/56 |
| FCF Yield | 12.55% | KR#552/2,405 Sec#7/56 |
| Profitability | ||
| ROE | 9.17% | KR#683/2,405 Sec#20/56 |
| ROA | 8.03% | KR#439/2,405 Sec#16/56 |
| Op. Margin | 10.29% | KR#506/2,405 Sec#13/56 |
| Revenue Growth | 14.11% | KR#714/2,405 Sec#18/56 |
| Financial Health | ||
| Debt Ratio | 14.24% | KR#228/2,405 Sec#7/56 |
| Total Debt | 6.00B KRW | KR#1,742/2,405 Sec#39/56 |
| FCF | 15.48B KRW | KR#587/2,405 Sec#14/56 |
| Cash | 8.89B KRW | KR#1,752/2,405 Sec#34/56 |
| Current Ratio | 5.06x | KR#278/2,405 Sec#5/56 |
| Net Debt/EBITDA | -0.20x | KR#567/2,405 Sec#17/56 |
| Dividend | ||
| Div. Yield | 1.71% | KR#987/2,405 Sec#24/56 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/56 |
| Performance | ||
| 1Y Return | -7.33% | KR#735/2,405 Sec#19/56 |
| 1M Return | -17.80% | KR#1,742/2,405 Sec#44/56 |
| From 52W High | -34.13% | KR#550/2,405 Sec#15/56 |
| 1Y MDD | -30.87% | KR#264/2,405 Sec#6/56 |
| Trading | ||
| Volume | 79,377 shares | KR#733/2,405 Sec#12/56 |
| Trading Value | 323.4M KRW | KR#957/2,405 Sec#19/56 |
| Foreign Own. | 2.82% | KR#1,344/2,405 Sec#24/56 |
| Per Share | ||
| EPS | 445 KRW | KR#1,039/2,405 Sec#28/56 |
| BPS | 4,852 KRW | KR#1,526/2,405 Sec#33/56 |
Company Info
Hyundaibioland was established in 1995 to manufacture and sell natural product cosmetic and functional food ingredients, listing on KOSDAQ in 2001. The company operates in cosmetic ingredients, health functional foods, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural-derived biomaterials. It focuses on discovering natural materials and R&D to enhance global competitiveness and develop next-generation Big Items through convergence technology, in response to stricter environmental regulations. Hyundaibioland is headquartered in Cheongju-si, Chungcheongbuk-do.